← Back to front page
Asia · Regional markets · Vietnam Investment Review

Delonix Bioworks partners with ASTAR on Klebsiella pneumoniae vaccine

Published by Vietnam Investment Review · Vietnam 1 d ago
Delonix Bioworks partners with ASTAR on Klebsiella pneumoniae vaccine
Delonix Bioworks partners with ASTAR on Klebsiella pneumoniae vaccine · Vietnam Investment Review

Detailed summary

Biotechnology firm Delonix Bioworks signed a research collaboration agreement with A*STAR Infectious Diseases Labs on 16 November 2026 to develop engineered outer membrane vesicle vaccines against Klebsiella pneumoniae.

SHANGHAI and SINGAPORE, Nov. 16, 2026 /PRNewswire/ -- Delonix Bioworks, a clinical-stage biotechnology company pioneering next-generation outer membrane vesicle (OMV) vaccines, today announced that it has entered into a Research Collaboration Agreement with A*STAR Infectious Diseases Labs (A*STAR IDL), a research institute under Singapore's Agency for Science, Technology and Research (A*STAR).

The collaboration aims to discover and develop novel OMV-based vaccine candidates targeting Klebsiella pneumoniae (K. pneumoniae). By combining Delonix's proprietary pathogenic bacterial genome editing and OMV Plus™ platforms with A*STAR IDL's strong capabilities in translational infectious disease research, clinical relevant bacterial isolates, and immunological evaluation, the collaboration also strengthens Singapore's capabilities to translate infectious disease research towards potential interventions against antimicrobial-resistant pathogens.

K. pneumoniae is a leading cause of life-threatening pneumonia, bloodstream infections, and sepsis, posing severe risks to vulnerable patient populations. The World Health Organization (WHO) has classified carbapenem-resistant Enterobacterales, including K. pneumoniae, as critical-priority pathogens due to high levels of multi-drug resistance against standard clinical therapies [1,2,3].

Despite the significant public health burden, there are currently no licensed vaccines available for K. pneumoniae. Traditional vaccine approaches have been hindered by the pathogen's extensive genetic diversity, thick capsular polysaccharides that mask conserved surface antigens, and high antigenic variation across hypervirulent and multidrug-resistant clinical lineages. Delonix's engineered OMV approach offers a differentiated solution to overcome these barriers.

This partnership marks an important milestone in Delonix's global strategy to build collaborative networks that accelerate the translation of next-generation bacterial vaccines.

Opening of the article, excerpted from Vietnam Investment Review. To read the rest, open the article on the publisher's site.

Read the full article on Vietnam Investment Review Sign in to save

MarketNews shows the headline and summary published by the outlet. The full article is on the publisher's website. (vir.com.vn)

Also worth reading